Artios Pharma Hooks Novartis & Pfizer In Over-Subscribed £65M Series B Round
With DNA damage repair pathways attracting a lot of attention as potential targets against various cancers, three-year old Artios Pharma has raised £65 million in an over-subscribed Series B round to fund the clinical development of its pipeline through to 2023.
You may also be interested in...
Cambridge, UK-based Artios Pharma attracted several new investors for its over-subscribed series B round in August 2018, but the company is yet to enter the clinic with its DNA repair drug portfolio and has many hurdles ahead to validate its technology. Scrip speaks to investors from LSP and Arix about why preclinical-stage biotechs are getting more attention in 2018.
Global financings for cell and gene therapy and tissue engineering companies more than doubled in the second quarter; financings for the sector rose 79% in the first half of 2018. Also, Samumed leads recent venture funding deals with a $438m round.
With a better understanding of how DNA damage repair (DDR) pathways operate in cancer cells, UK biotech Artios Pharma, in partnership with Cancer Research UK, is looking to develop drug candidates that can selectively kill tumor cells. Speaking at the Biotech Showcase 2018, Artios CEO Niall Martin told Scrip how the company is advancing its lead programs towards the clinic and is seeking series B venture capital to demonstrate proof of concept for the lead programs.